238 related articles for article (PubMed ID: 35958877)
1. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
2. Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
Fang F; Lu J; Sang X; Tao YF; Wang JW; Zhang ZM; Zhang YP; Li XL; Xie Y; Wu SY; Chu XR; Li G; Wu D; Chen YL; Yu JJ; Jia SQ; Feng CX; Tian YY; Li ZH; Ling J; Hu SY; Pan J
J Exp Clin Cancer Res; 2022 Jul; 41(1):225. PubMed ID: 35842703
[TBL] [Abstract][Full Text] [Related]
3. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
[TBL] [Abstract][Full Text] [Related]
4. The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes.
Yu J; Yang Y; Zhou R; Tao YF; Zhu F; Jiao W; Zhang Z; Ji T; Li T; Fang F; Xie Y; Wu D; Zhuo R; Li X; Chen Y; Yin H; Wang J; Pan J
Carcinogenesis; 2024 Feb; ():. PubMed ID: 38302114
[TBL] [Abstract][Full Text] [Related]
5. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
[TBL] [Abstract][Full Text] [Related]
6. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
7. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
8. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
[TBL] [Abstract][Full Text] [Related]
9. m
Zhao Y; Zhou Y; Qian Y; Wei W; Lin X; Mao S; Sun J; Jin J
Clin Transl Med; 2024 Apr; 14(4):e1628. PubMed ID: 38572589
[TBL] [Abstract][Full Text] [Related]
10. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
Zhang K; Gao L; Wang J; Chu X; Zhang Z; Zhang Y; Fang F; Tao Y; Li X; Tian Y; Li Z; Sang X; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Hu S
Pathol Oncol Res; 2022; 28():1610447. PubMed ID: 35832114
[TBL] [Abstract][Full Text] [Related]
11. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
[TBL] [Abstract][Full Text] [Related]
12. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
[No Abstract] [Full Text] [Related]
13. Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia.
Baragaño Raneros A; Rodriguez RM; Bernardo Flórez A; Palomo P; Colado E; Minguela A; Suárez Álvarez B; López-Larrea C
Oncoimmunology; 2021 Mar; 10(1):1897294. PubMed ID: 33796404
[TBL] [Abstract][Full Text] [Related]
14. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
15. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
16. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
17. NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.
Shen C; Ipsaro JJ; Shi J; Milazzo JP; Wang E; Roe JS; Suzuki Y; Pappin DJ; Joshua-Tor L; Vakoc CR
Mol Cell; 2015 Dec; 60(6):847-59. PubMed ID: 26626481
[TBL] [Abstract][Full Text] [Related]
18. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S; Fong CY; Grove C; Craig J; Dittmann A; Lugo D; Jeffrey P; Drewes G; Lee K; Bullinger L; Prinjha RK; Kouzarides T; Vassiliou GS; Huntly BJ
Leukemia; 2014 Feb; 28(2):311-20. PubMed ID: 24220271
[TBL] [Abstract][Full Text] [Related]
19. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
[TBL] [Abstract][Full Text] [Related]
20. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]